



How many drugs are approved each year?




The approvals per year starts to go in an exponential trend in 1971 and rise till 2002 when there we observe a steep decline after which the number of approvals start increasing again but don't reach to levels of 2002.

Trend of approval each year by sponsor



- Noticeable upward trend is seen for most Sponsors till the 2000s after which the trend become downwards suggesting possibilities like strict norms after 2002 or increasing health of people or saturation of market.
- Hospira has the highest approvals throughout the years on an average. It along with Sandoz, Teva, Watson Labs, Mylan dominate the approval counts majorly.
- There is evidence that newer and smaller players can gain traction which shows there is a diverse landscape and opportunities for anyone to thrive.
- With the downward trend we can see the established companies losing ground to newer ones.

Segmentation of Products based on Marketing Status



Majority of the products are in the "Marketed" stage which means they are on sale and completed regulatory compliance. But the FDA should focus their efforts on the "Pending" category as around 14 k drugs are pending for approval, this shows that there is a significant backlog for the Authority to work upon.

The Withdrawn column shows that only around 700 drugs have been taken off market or rejected for approval, this can mean the R&D of companies before applying is robust or the standards of FDA are lax where almost all drugs are getting approved.

Year

All


Market

Pending

Pre-Market

Withdrawn

Total Application numbers by Marketing status and Year of Approval



Form	Count of drugname
TABLET;ORAL	13942
INJECTABLE;INJECTION	6172
CAPSULE;ORAL	3316
TABLET, EXTENDED RELEASE;ORAL	1501
CAPSULE, EXTENDED RELEASE;ORAL	706
TABLET; ORAL	491
CREAM;TOPICAL	457
SOLUTION;ORAL	390
SOLUTION/DROPS;OPHTHALMIC	387
FOR SUSPENSION;ORAL	346
TABLET, ORALLY DISINTEGRATING;ORAL	325
SYRUP;ORAL	317
OINTMENT;TOPICAL	244
TABLET, DELAYED RELEASE;ORAL	240
INJECTABLE; INJECTION	223
SUSPENSION;ORAL	222
TABLET, CHEWABLE;ORAL	200
INJECTABLE;IV (INFUSION)	197
TABLET;ORAL-28	196
SOLUTION;TOPICAL	192
FILM, EXTENDED RELEASE;TRANSDERMAL	184
INJECTABLE;INTRAVENOUS	169
Total	34465

Form	NumDrugsApproved
TABLET;ORAL	11645
INJECTABLE;INJECTION	4939
CAPSULE;ORAL	2590
TABLET, EXTENDED RELEASE;ORAL	1365
CAPSULE, EXTENDED RELEASE;ORAL	631
SOLUTION;ORAL	355
CREAM;TOPICAL	344
SOLUTION/DROPS;OPHTHALMIC	331
TABLET, ORALLY DISINTEGRATING;ORAL	323
FOR SUSPENSION;ORAL	282
SYRUP;ORAL	240
TABLET, DELAYED RELEASE;ORAL	216
INJECTABLE;IV (INFUSION)	195
TABLET, CHEWABLE;ORAL	190
TABLET;ORAL-28	189
FILM, EXTENDED RELEASE;TRANSDERMAL	184
OINTMENT;TOPICAL	183
SUSPENSION;ORAL	173
INJECTABLE;INTRAVENOUS	163
SOLUTION;TOPICAL	160
CAPSULE, DELAYED REL PELLETS;ORAL	153
INJECTABLE;SUBCUTANEOUS	140
Total	28339

Most Successful Dosage form

TABLET;ORAL
11645

Therapeutic Class with the highest number of Drug Approvals -

AB

10555

Number of Drugs approved according to TECode

